comparemela.com

Latest Breaking News On - நிபுணர் ஒருமித்த கருத்து - Page 1 : comparemela.com

China s first COVID-19 department established to normalize future coronavirus treatment

CHINA / SOCIETY By Du Qiongfang Published: Dec 27, 2020 05:23 PM Two medical staffers at a designated plasma collection center of the Shanghai Public Health Clinical Center Photo: Chen Xia/GT Shanghai Public Health Clinical Center has set up China s first COVID-19 department with closed-loop management in a bid to normalize the management and treatment of infectious diseases and ensure the novel coronavirus outbreak is put under control quickly as new variants emerge.  As the city s designated hospital in treating adult patients with infected COVID-19, the center has accumulated rich experience in clinical treatment of the coronavirus over the past year. Over 1,000 imported patients were treated at the center recently. 

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease

Bruno Dubois Bruno Dubois is currently Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital at Paris, University Pierre et Marie Curie Paris VI. He is Director of the Behavioural Neurology Department and of the Dementia Research Center at the Hospital. He is also Director of the Research Unit Inserm U-610 of the ICM (Institut du Cerveau et de la Moelle Epinière) of the Hospital. He is coordinator of the National Reference Center on Rare Dementias and of the National Reference Center for young-onset Alzheimer patients. He is President of the Scientific Committee of France-Alzheimer and of IFRAD (International Fund Raising for Alzheimer s disease), consultant for the Human Frontier Program and Expert of the French Agency of Drugs. He is a member of the European Alzheimer Disease Consortium (EADC). He has published on anatomical and biochemical studies on the central cholinergic systems in rodents and humans; on cognitive neuropharmacology; an

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease Paris Stock Exchange:AB

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease Paris Stock Exchange:AB
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease – IT Business Net

AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer s disease – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.